Renaissance Technologies LLC lessened its stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 48.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,700 shares of the company’s stock after selling 52,100 shares during the period. Renaissance Technologies LLC’s holdings in Outlook Therapeutics were worth $71,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership bought a new position in Outlook Therapeutics in the 3rd quarter worth approximately $36,000. GWM Advisors LLC acquired a new position in Outlook Therapeutics in the fourth quarter valued at about $26,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Outlook Therapeutics by 103.5% in the fourth quarter. Bank of New York Mellon Corp now owns 103,515 shares of the company’s stock valued at $135,000 after buying an additional 52,657 shares in the last quarter. 3.04% of the stock is currently owned by institutional investors.
NASDAQ:OTLK opened at $1.87 on Thursday. The company has a market cap of $324.64 million, a PE ratio of -1.50 and a beta of 0.46. Outlook Therapeutics, Inc. has a one year low of $0.58 and a one year high of $4.26. The firm’s 50 day simple moving average is $2.18 and its 200 day simple moving average is $1.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.13 and a quick ratio of 1.13.
In other Outlook Therapeutics news, Director Ghiath M. Sukhtian acquired 8,360,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 2nd. The stock was bought at an average cost of $1.00 per share, with a total value of $8,360,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Terry Dagnon sold 15,900 shares of Outlook Therapeutics stock in a transaction on Tuesday, February 23rd. The shares were sold at an average price of $2.09, for a total value of $33,231.00. Following the completion of the transaction, the chief operating officer now owns 1,127,857 shares of the company’s stock, valued at $2,357,221.13. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 145,127 shares of company stock worth $358,825. 4.00% of the stock is owned by corporate insiders.
Several research firms have recently issued reports on OTLK. Zacks Investment Research lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 10th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $6.00 price target on shares of Outlook Therapeutics in a research report on Wednesday, February 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Outlook Therapeutics currently has a consensus rating of “Buy” and an average price target of $5.38.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.